Advanced Hysteroscopy Hands-on Course

Recently, the inaugural congress of the International Society of Obstetrics‑Gynecology Ablation (ISOGA) concluded successfully in the Philippines, opening a brand‑new chapter for minimally‑invasive ablation diagnosis and treatment in global obstetrics and gynecology. Major good news emerged from the event: Professor Gong Xiaoming, chief expert at Woyi Minimally‑Non‑Invasive Medicine, has been appointed Chair of ISOGA. This appointment stands as high‑recognition from the international medical community for his years‑long dedication to gynecological minimally‑ and non‑invasive therapy. It also serves as vital proof that Chinese minimally‑invasive gynecological techniques have stepped onto the international forefront. His well‑deserved achievement rewards his long‑term devotion to this field.

The 3rd Annual Scientific Meeting of the Singapore Society of Gynecological Minimally Invasive Surgery (SGMIS) was successfully held in Singapore on July 24–25, 2026. As a high-profile academic event in the field of gynecological minimally invasive surgery, the meeting gathered global experts to share cutting-edge research results and clinical practical experiences.

A research team led by Professor Xiang Yang from Peking Union Medical College Hospital joined forces with Professor Sun Pengming’s team from Fujian Maternity and Child Health Hospital to publish a landmark research finding in a journal of the Nature portfolio. The study systematically elucidates the dichotomous oncogenic role of CD112, a novel immune checkpoint, in cervical cancer progression, which simultaneously mediates tumor immunosuppression and ferroptosis metabolic resistance. This finding breaks the inherent limitations of single-target immunotherapy for cervical cancer and delivers an innovative combinatorial target and translational theoretical foundation for overcoming PD-1 inhibitor resistance in patients with advanced cervical cancer in clinical practice.

the 14th OB/GYN Network Surgical Video Competition embarks on a new journey. Submission of entries is now open nationwide. We sincerely invite young and middle-aged physicians from all regions to submit entries, showcasing your superb surgical skills and sharing clinical experience with fellow practitioners.

Can I still get pregnant if fibroids or ovarian cysts are detected during pre-pregnancy planning? What are the risks associated with having a second or third child at an advanced maternal age? Is painless childbirth safe? What should men do to prepare for conception? Recently, the National Health Commission of China (NHCC) held a press conference themed "Promoting Reproductive Health." Several top medical experts were invited to provide professional answers to common public concerns regarding fertility, pregnancy, childbirth, and the postpartum period, while also sharing the latest progress in national reproductive health services across China.

From June 10 to 13 local time, the 51st Annual Meeting of the International Association of Gynecology and Urology (IUGA) grandly opened in Rio de Janeiro, Brazil. As the highest-level and most influential academic event in the global field of pelvic floor urogynecology, this year's conference innovatively features the Balloon Debate session, focusing on the "optimal treatment plan for recurrent anterior vaginal prolapse after hysterectomy." Multiple rounds of expert competitions will be held, using innovative interactive formats to spark diagnostic and treatment ideas, fully demonstrating an open and inclusive international academic atmosphere in the pelvic floor field, centered on patient benefit. It provides a new reference paradigm for domestic academic exchange in the pelvic floor.

On June 25, 2026, Merck announced that its PD-1 inhibitor pembrolizumab (brand name: Kreida ®) has received approval from China's National Medical Products Administration (NMPA) for the use of a well-validated test to evaluate the treatment of adult patients with platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have previously received first- or second-line systemic therapy who have expressed PD-L1 (Composite Positive Score (CPS)≥1). The approval of this new indication is based on data from the Phase III clinical trial KEYNOTE-B96 (ENGOT-ov65).

Recently, the team led by Academician Huang He feng​ of Zhejiang University published landmark findings in Nature. The team successfully constructed the world's first spatiotemporal dynamic transcriptomic atlas of human embryos during the post-gastrulation and early organogenesis stages. This breakthrough resolves a long-standing research challenge in the field, showcasing the cutting-edge scientific capabilities of China's obstetrics and gynecology community to the international academic world, while providing milestone data support for clinical and basic research in birth defect prevention, reproductive medicine, and fetal medicine.

In April 2026, the team led by Academician Jie Qiao​ of Peking University Third Hospital published original research findings in the internationally renowned journal Nature Communications. Based on mouse models, the study is the first to confirm that the endogenous small molecule uridine​ can effectively reverse aging in oocytes and significantly enhance fertility. It elucidates the core mechanism by which uridine targets PCBP1, inhibits ferroptosis, and repairs mitochondrial function. This provides a potentially translatable, China-originated intervention strategy for addressing global female reproductive aging, garnering significant attention in the field of reproductive medicine worldwide.